Shasun Pharmaceuticals rises on receiving USFDA approval for Carisoprodol Tablets

16 Nov 2015 Evaluate

Shasun Pharmaceuticals is currently trading at Rs. 404.60, up by 6.65 points or 1.67% from its previous closing of Rs. 397.95 on the BSE.

The scrip opened at Rs. 398.25 and has touched a high and low of Rs. 408.00 and Rs. 395.60 respectively. So far 13,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 415.95 on 20-Aug-2015 and a 52 week low of Rs. 209.80 on 17-Nov-2014.

Last one week high and low of the scrip stood at Rs. 408.00 and Rs. 368.40 respectively. The current market cap of the company is Rs. 2,721.00 crore.

The promoters holding in the company stood at 35.32%, while Institutions and Non-Institutions held 20.41% and 44.27% respectively.

Shasun Pharmaceuticals has received an approval from the United States Food & Drug Administration (USFDA) for Carisoprodol Tablets USP 250 mg and 350 mg. The product will be manufactured at the Pondicherry facility of the company and will be distributed in US through a partner. The product is expected to be launched shortly.

Carisoprodol Tablets 250 mg & 350 mg has sales of approximately $38 million. While the 350 mg has few Generic players, Shasun expects to be the first marketed generic player in the $16 million Carisoprodol Tablets 250 mg opportunity.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.


Peers
Company Name CMP
Sun Pharma Inds. 1486.35
Dr. Reddys Lab 5962.50
Cipla 1400.00
Zydus Lifesciences 933.40
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.